Clinical trial · Interventional
Clinical Impact of Dedicated MR Staging of Ovarian Cancer
NCT03399344CI-TRIAL-00033047MRStagingOCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The only chance of cure for patients with advanced stage ovarian cancer is complete cytoreductive surgery (CRS). The only way to determine whether complete CRS can be achieved is by a laparoscopy. However, diffusion-weighted magnetic resonance imaging (DW-MRI) has a very high sensitivity to detect small volume malignant disease, making it a potentially suitable staging tool. Aim of this study is to determine the performance of DW-MRI for predicting whether complete CRS can be achieved.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- DW-MRI
- description
- Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
- interventionNames
- Other: MRI
Primary outcomes (1)
- measure
- Diagnostic performance of DW-MRI to predict a complete cytoreductive surgery
- timeFrame
- 1 month
- description
- Patients will undergo an additional MRI, besides their regular diagnostic workup, for assessing the extent of peritoneal carcinomatosis. Whether or not complete cytoreductive surgery is feasible will be determined on DW-MRI independently by two radiologists. The outcome wil be defined as the number of cytoreductive procedures correctly predicted by DW-DWI.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced stage (FIGO stage III or IV) ovarian cancer scheduled for primary or interval cytoreductive surgery * Age \>18 years * Written and signed informed consent * WHO 0-2 * Able to read and write Dutch Exclusion Criteria: * Patients with contraindications for MRI * Patients with contraindications for CRS * Known additional malignancy
References
Publications (1)
- DERIVEDBerardi E, J van Driel W, H M Hermans R, N Gaarenstroom K, A R Lok C, Persijn-van Meerten ELV, Nederend J, Lambrechts S, Lopez-Yurda M, P Engbersen M, J V Rijsemus C, M J Lambregts D, Laghi A, G J Aalbers A, G H Beets-Tan R, F M Kok N, J Lahaye M. MRI in advanced ovarian cancer: multicentre MISSION trial. Eur J Cancer. 2026 May 2;238:116614. doi: 10.1016/j.ejca.2026.116614. Epub 2026 Feb 26. PMID 41780181